Arrowhead Research | ARWR - Net Income


Arrowhead Research reported $-132.73M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD -132.73M 163.54M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Incyte USD 585.6M 282.27M Jun/2026
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
Ligand Pharmaceuticals USD 48.51M 61.85M Jun/2026
Merck USD -1.34B 2.9B Jun/2026
Moderna USD -1.34B 517M Mar/2026
Nektar Therapeutics USD -44.9M 8.82M Mar/2026
Novartis USD 3.26B 108M Jun/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
TG Therapeutics USD 7.78M 12M Jun/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vertex Pharmaceuticals USD 1.1B 68.4M Jun/2026
Xencor USD -21.73M 107.19M Jun/2026